Eisai Forges Small Molecule Research Pact with Wren Therapeutics
Japan’s Eisai and UK drugmaker Wren Therapeutics have signed a collaboration agreement to develop small molecule therapies for treatment of protein misfolding diseases, such as Parkinson’s disease, Lewy body dementia and multiple system atrophy.
The conditions represent a “significant unmet medical need” since they don’t currently have any effective treatments, said Teiji Kimura, Eisai’s chief discovery officer.
Wren has pioneered a new approach to protein misfolding diseases that uses a predictive method in place of the traditional drug discovery and biological approaches.
Financial terms of the collaboration agreement were not disclosed.